Technology
At the core of Faraday Bio's technology is electrophoresis. Our proprietary microfluidic system is capable of running any electrophoretic method at high resolution and reproducibly isolating all variants for subsequent analysis. No more struggling to correlate results from orthogonal techniques – What you see is what you get!
To learn more contact us below or follow us on LinkedIn!
Erik Gentalen
Erik Gentalen is CEO and co-founder of Faraday Bio and the co-inventor of its core technologies, with more than 20 years of experience building analytical systems for biologic drug and protein analysis. Over his career, Erik has developed and applied a problem-first, use-case-driven approach that emphasizes deep understanding of scientific and customer needs before designing technical solutions that fit real-world workflows and regulatory requirements, resulting in strong product-market fit.
He was the founder and inventor of Intabio’s core microfluidic platform, which integrates electrophoretic separation with direct structural characterization to enable real-time, simultaneous multi-attribute monitoring. The technology progressed from initial funding to acquisition in 3.5 years and is now commercialized globally as the Intabio ZT system by SCIEX. Previously, Erik led development of the Simple Western platform at ProteinSimple from invention through launch and earlier contributed to foundational microfluidic and genomics technologies at Caliper and Affymetrix. He is an inventor on more than 50 issued patents and holds a BS in Biology from MIT.
Scott Mack
Scott Mack is CSO and co-founder of Faraday Bio and a co-inventor of its core technologies, with a career focused on developing protein separation products and assays for biopharmaceutical research and drug development. Earlier in his career, Scott played a key role in advancing electrophoresis-based platforms that became widely adopted in biologics analysis, including the development of the Maurice system at ProteinSimple, long regarded as a gold standard for protein charge characterization.
He was a principal scientist at Intabio, where he led cross-functional teams in the conception and development of a transformative multi-attribute monitoring platform that reduced the time required to identify and characterize biotherapeutic proteoforms from weeks to minutes; following Intabio’s acquisition by SCIEX, he continued to advance novel bioanalytical workflows in collaboration with more than 30 pharmaceutical partners. Previously, Scott held senior scientific roles at ProteinSimple and Beckman Coulter, contributing to the development of capillary electrophoresis systems and mass spectrometry–integrated workflows used across research and regulated environments. He is an inventor on 23 issued patents and holds an MS in Information Systems and a BS in Biochemistry from California State University, Fullerton.